mobile version

HOME/OVERVIEW
MESOTHELIOMA
Pleural Mesothelioma/Peritoneal
Mesothelioma Symptoms
  and Diagnosis
Mesothelioma Staging
Treatment Options
Alimta Medication
Mesothelioma Clinical Trials
LUNG CANCER INFORMATION
Types of Lung Cancer
Lung Cancer Symptoms
Lung Cancer Staging
Lung Cancer Treatment Options
CANCER HOSPITALS
Locations By State
Questions and Information
 From Your Doctor
AT RISK JOBS
VETERAN'S RESOURCES
VA Hospitals, Clinics, & Centers
Veteran Service Officers
History, Ships, & Shipyards
CANCER INFORMATION RESOURCES
Mesothelioma News
Patient Stories
Web Resources
Patient Handout
Glossary of Terms
SITE MAP
Contact us

 Search for information:
 
      Match:
any search words
all search words

Click Here for a Free
Information Packet

FOR MORE INFORMATION
Please call
1-800-400-1805

We will gladly answer your
questions and send a free
packet with additional
information on:

  • New treatment options
  • New clinical trials
  • Doctors
  • Hazardous jobs and products
  • Veteran's Resources
  • Financial Assistance

 

 

 





Lung Cancer and Mesothelioma Information
    
1-800-400-1805

 

 

Mesothelioma and Lung Cancer News - Return to Menu

New drug to aid SA fight against asbestos-linked cancer

May 31, 2006 - In response to an urgent need to improve local treatment for anexcruciating form of asbestos-related cancer, international corpo-ration Lilly has recently released a drug that promises to ease its symptoms when other treatments fall short.

Alimta (Pemetrexed), when used with cisplatin – another widely used chemotherapy drug – is the first and only drug to be approved by the Food and Drug Association for the treatment of patients with mesothelioma when surgery is not an option. Treatments such as this one are highly relevant in South Africa, where asbestos-related illnesses are painfully prevalent.

“Control has come from thebottom up, with protests by unions and workers on the painful effects of mesothelioma. This has brought attention to the disease in South Africa,” said Prof Raymond Abratt, head of the oncology department at Grootte Schuur Hospital in Cape Town, speaking at a media con-ference on treatment options formesothelioma. Resistant to fire and heat and imbued with strength and flexibility, asbestos is a remarkable material that found many uses duringthe industrial era.

With deposits located primarilyin the Northern Cape, the North West province, Limpopo province and Mpumalanga, asbestos miningin South Africa began in earnest in the 1930s and during the following decades attracted a multitude of companies. This has left alegacy of individuals sufferingasbestos-related illnesses, one of which is mesothelioma. Working with asbestos constitutes a major risk factor for mesothelioma,with a history of work with asbestosreported in up to 80% of all cases. The risk of asbestos-related diseaseincreases with heavier exposure to asbestos and longer exposure time. Mesothelioma is cancer of the mesothelium, a membrane that coversand protects most of the internalorgans of the body. This lethal form of cancer causes the cells of the mesothelium to become abnormal and divide without control or order. These cells can invade and damagenearby tissues and organs. The cancercells can also spread from their original site to other parts of the body. Malignant mesothelioma moves through four stages, each one more severe than the next, culminating in cancer spreading into the chest wall, centre of the chest, diaphragm or stomach. As a result of the sheer volume of asbestos mined in South Africa, the incidence of mesothelioma in the country is among the highest in the world, and six times higher than the UK. The male:female ratio is 2,5: 1 and incidence increases with age from the fifth decade onwards, peaking after the age of 70. “The most curious thing about this illness is the length of time that can elapse between exposure and manifestation,” says Prof. Hilary Calvert, professor of medicaloncology for the Northern Institute for Cancer Research.

Mesothelioma can develop 20 or more years after the first exposure, while the peak incidence is between 35 and 45 years after exposure. The production of crocidolite, also known as blue asbestos, peaked in 1977.

Therefore, all those exposed during the 1970s and 1980s will be approaching the peak in their occurrence of malignant mesothelioma. It is expected that the incidence of mesothelioma will continue at least for the lifetime of those largenumbers of people exposed to crocido-lite in mining and in industry. Therefore, not only the miners, but their families and those exposed to asbestos through other means have a chance of developing the disease. “In our country, we had a patient who developed mesothelioma at 32. The reason for this was that, when she was young, one asbestos factory allowed peopleto obtain free materials for theirgardens from their grounds. Herparents had used this material, and the woman had been exposed by playing in the garden as a young girl,” states Prof Johan Vansteenkiste of the respiratory oncology unit of the University Hospital Gasthuisberg, in Belgium. There is debate over how much exposure is needed to develop mesothelioma. There have been cases reported where exposure has been as short as a few months. Mesothelioma has also been reported in some individuals without any known exposure to asbestos.

Treatment of the disease depends on the location of the cancer, the stage of the disease, and the patient’s age and general health. However, the nature of the disease is such that by the time it has been diagnosed, it is often in its advanced stages and beyond complete surgical excision and possible cure. These options include surgery, radiation therapy and chemotherapy either administered singularly or combined. Alimta is used alongside chemotherapy treatments that use drugs to destroy cancer cells throughout the body.

It works by interfering with a crucial process that allows cancercells to reproduce and spread. Speci-fically, Alimta works by stopping theproduction of three enzymes thatare required to feed the cancer cell. To date, Lilly’s drug has found success in a number of patients who underwent the treatment. Dr Daniel Osei-fofie, a medical doctor practising in Kimberly, told the meeting that he started trial treatments with Alimta in February 2005.

The new drug was used on a 54-year old man, who worked on a Northern Cape asbestos-mine for six years. He reported that the patient had returned to work in February this year after five treatments. “Previously, we could not offer much to these patients,” he said.



To Obtain the Best Treatment Info & Financial Assistance contact us for a FREE INFORMATION PACKET which includes:

Doctors & Cancer Hospitals
Clinical Trials
Hazardous Jobs/ Products
New Treatment Options
Veteran's Resources
Financial Assistance

Fill out the form below or call 1-800-400-1805.

Use the "tab" key to move to the next field, not enter.

First Name
Last Name
Address
City
State
Zip

Phone

Email
 

Have you or a loved one been diagnosed or have:
   
Mesothelioma:

Yes   No
Lung Cancer:

Yes   No
Had a biopsy?:


Yes   No
Did you or your loved one work around asbestos?:
Yes   No
 

Comment /
Info Request

Please just hit the order button once, then wait for the form to be sent

 

Site Map | Mesothelioma | Alimta | Lung Cancer | Non-small cell lung cancer | Small cell lung cancer | Asbestos Lung Cancer | Lung Cancer Symptoms | Mesothelioma News | Mesothelioma Symptoms | Pleural Mesothelioma | Symptoms | Breaking News | Patient Handout | Treatment | Mesothelioma Patients | Mesothelioma Causes | Mesothelioma Climical Trials | Mesothelioma treatment | Veteran's Resources | Mesothelioma Treatments